Scandal Aside, Biogen’s Aduhelm Sales Set to Reach $1B Next Year and $6B+ by 2025: Analysts

From: FiercePharma

By: Noah Higgins-Dunn

The analysts based the belief on the latest survey results from Spherix Global Insights, which suggest a very gradual uptake so far. In the first month since its approval, the survey found two neurologists—or 2% of respondents—prescribed the treatment for three patients…(read more)